Nuchev Limited

NUC.ASX

Consumer Staples

Developing, marketing and selling a range of premium Australian made goat nutritional products.

Market Data

Price

$0.150

+0.2%
Market Cap

$23.5M

P/E Ratio

-100000.0x

EPS

$-0.031

Div. Yield

0.00%

52-Week Change

-0.1%

Latest Earnings

Appendix 4D and Half Year Report

24 February 2026

Revenue
$12.38
+12.0% YoY
NPAT
-$2.34
+48.2% YoY
EPS
$-0.02

Nuchev Limited reported 12.0% revenue growth to $12.38 million for the half-year ended 31 December 2025, driven by strong Oli6® sales, the bWellness acquisition, and expansion into Vietnam. However, the net loss widened 48.2% to $2.34 million due to increased investment in marketing, product development, and operational scaling, while gross margins compressed from 48.2% to 46.2%. The company remains debt-free with $3.1 million cash and access to undrawn working capital facilities. Key points: Revenue grew 12.0% to $12.38 million driven by Oli6® brand strength and bWellness acquisition contribution; Successfully expanded into Vietnam market with sales through Mother & Baby stores and online channels; Strong performance in established Australian Pharmacy and Grocery channels

Recent Announcements

24 Feb 2026 Supplementary Neutral

Investor Presentation - Half Year Results to 31 Dec 25

Nuchev Limited reported revenue growth to $12.4M for H1 FY26, up 12.7% from $11.0M in the prior period, driven by continued demand across core channels. However, the company remains in an investment phase with EBITDA loss widening to $(2.1)M from $(1.5)M and statutory net loss increasing to $(2.3)M from $(1.6)M. The company maintains adequate liquidity with $3.1M cash and focuses on building operational scale toward profitability. Key points: Revenue grew 12.7% to $12.4M driven by continued demand across core channels; Australian domestic retail remained resilient and in growth as the core stable channel; Improved marketing execution supporting underlying consumer demand

24 Feb 2026 Actual Results Negative

Appendix 4D and Half Year Report

Nuchev Limited reported 12.0% revenue growth to $12.38 million for the half-year ended 31 December 2025, driven by strong Oli6® sales, the bWellness acquisition, and expansion into Vietnam. However, the net loss widened 48.2% to $2.34 million due to increased investment in marketing, product development, and operational scaling, while gross margins compressed from 48.2% to 46.2%. The company remains debt-free with $3.1 million cash and access to undrawn working capital facilities. Key points: Revenue grew 12.0% to $12.38 million driven by Oli6® brand strength and bWellness acquisition contribution; Successfully expanded into Vietnam market with sales through Mother & Baby stores and online channels; Strong performance in established Australian Pharmacy and Grocery channels

Get real-time alerts for NUC

Receive AI-powered earnings summaries and instant notifications when Nuchev Limited releases results.

Register Free